Eliquis Tablet, Film Coated
Product Images NDC 50090-6451

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Eliquis (NDC 50090-6451). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Apixaban Chemical Structure (Apixaban Struct)

Chemical structure of apixaban, the active ingredient in ELIQUIS 2.5 mg film-coated tablets. The diagram shows the molecular structure with rings and functional groups typical of apixaban.*

FDA Label Image

Aristotle Forest Plot (Eliquis Clin Forest Fig5)

A forest plot chart comparing the hazard ratios for various subgroups of patients taking apixaban versus warfarin. The chart lists subgroups by prior warfarin/VKA status, age, sex, weight, prior stroke or TIA, diabetes mellitus, CHADS2 score, creatinine clearance, geographic region, and aspirin use at randomization. Each subgroup shows hazard ratios with confidence intervals, indicating relative risk for apixaban compared to warfarin.*

FDA Label Image

Aristotle Major Bleeding Forest Plot (Eliquis Forest Fig1)

A forest plot chart comparing the number of events per patient-year and hazard ratios for apixaban versus warfarin across various patient subgroups such as age, sex, weight, diabetes status, and geographic region. The chart visually displays hazard ratios with 95% confidence intervals, indicating comparative effectiveness between apixaban and warfarin.*

FDA Label Image

Aristotle Kaplan-meier Curve (Eliquis Km Fig4)

A Kaplan-Meier curve comparing the proportion of subjects experiencing stroke or systemic embolism over 36 months between ELIQUIS (apixaban) and Warfarin. The graph shows cumulative event rates with ELIQUIS having fewer events (212/9120) than Warfarin (265/9081). Numbers at risk for both treatments are listed below the time axis.*

FDA Label Image

Effect Of Coadministered Drugs On Pharmacokinetics Of Apixaban (Eliquis Pkplot Drugs Fig2)

A pharmacokinetic chart showing the fold change and 90% confidence intervals in Cmax and AUC relative to reference for various interacting drugs with combined P-gp and strong CYP3A4 inhibitors, other CYP3A4 and P-gp inhibitors, and a combined P-gp and strong CYP3A4 inducer. Drugs include ketoconazole 400 mg, clarithromycin 500 mg, diltiazem 360 mg, naproxen 500 mg, and rifampin 600 mg, with values plotted on a horizontal axis representing change relative to reference from 0.5 to 2.0.*

FDA Label Image

O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)

A pharmacokinetic chart showing fold changes and 90% confidence intervals for apixaban concentration (Cmax) and area under the curve (AUC) across different patient populations, including varying degrees of renal impairment, age, body weight, and hepatic impairment. Recommendations regarding dose adjustments based on these pharmacokinetic changes are also provided.*

FDA Label Image

Label Image (Lbl500906451)

Label for ELIQUIS 2.5 mg film-coated tablets containing apixaban, an oral human prescription drug. The label indicates a package of 60 tablets by A-S Medication Solutions, Libertyville, Illinois. It includes storage instructions to keep at 68 to 77 degrees Fahrenheit and a QR code for dosage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.